Osamu Tanaka1, Takao Kojima2, Akihiro Ohbora2, Chiyoko Makita3, Takuya Taniguchi1, Kousei Ono1, Masayuki Matsuo4, Yasushi Nagata5. 1. Asahi University Hospital, Department of Radiation Oncology, Gifu, Japan. 2. Asahi University Hospital, Department of Gastroenterology, Gifu, Japan. 3. Gifu Prefectural General Medical Center, Department of Radiation Oncology, Gifu, Japan. 4. Gifu University Hospital, Department of Radiology, Gifu, Japan. 5. Hiroshima University Hospital, Department of Radiation Oncology, Hiroshima, Japan.
Abstract
BACKGROUND: Stereotactic body radiotherapy (SBRT) delivers high-dose radiation to tumor tissues in few fractions, thereby reducing radiation damage to at-risk organs. There are more potential effects of SBRT owing to the higher biological equivalent dose delivered. Herein, we retrospectively analyzed its effectiveness and toxicity at our institution. METHODS: Data from patients with hepatocellular carcinoma (HCC; n = 10) and liver metastases (n = 10) who underwent SBRT (total dose of 30-50 Gy in 5-10 fractions) between 2013 and 2016 were analyzed. Adverse events were recorded at the end of RT, 6 months after treatment, or upon death. Overall survival (OS) was calculated according to the biological effective dose (BED α/β = 10) and liver function (Child-Pugh [CP] classification 5 or 6 vs. 7 or 8) after SBRT, using Kaplan-Meier analyses. RESULTS: Of the 20 patients, 6 declined the CP classification score after SBRT; grade 3 adverse events were not seen in any patient. A higher OS rate was seen in patients receiving a higher BED and in those with better CP classification after SBRT. Kaplan-Meier survival analysis yielded a median OS of 401 days and 1- and 2-year OS of 45% and 15%, respectively. CONCLUSION: The higher BED was significantly associated with tumor control, and there were no differences in the tumor control rate between HCC and metastatic tumors. Changes in CP scores after SBRT also affected the survival rate. Good liver function may permit multiple rounds of SBRT.
BACKGROUND: Stereotactic body radiotherapy (SBRT) delivers high-dose radiation to tumor tissues in few fractions, thereby reducing radiation damage to at-risk organs. There are more potential effects of SBRT owing to the higher biological equivalent dose delivered. Herein, we retrospectively analyzed its effectiveness and toxicity at our institution. METHODS: Data from patients with hepatocellular carcinoma (HCC; n = 10) and liver metastases (n = 10) who underwent SBRT (total dose of 30-50 Gy in 5-10 fractions) between 2013 and 2016 were analyzed. Adverse events were recorded at the end of RT, 6 months after treatment, or upon death. Overall survival (OS) was calculated according to the biological effective dose (BED α/β = 10) and liver function (Child-Pugh [CP] classification 5 or 6 vs. 7 or 8) after SBRT, using Kaplan-Meier analyses. RESULTS: Of the 20 patients, 6 declined the CP classification score after SBRT; grade 3 adverse events were not seen in any patient. A higher OS rate was seen in patients receiving a higher BED and in those with better CP classification after SBRT. Kaplan-Meier survival analysis yielded a median OS of 401 days and 1- and 2-year OS of 45% and 15%, respectively. CONCLUSION: The higher BED was significantly associated with tumor control, and there were no differences in the tumor control rate between HCC and metastatic tumors. Changes in CP scores after SBRT also affected the survival rate. Good liver function may permit multiple rounds of SBRT.
Authors: Søren M Bentzen; Louis S Constine; Joseph O Deasy; Avi Eisbruch; Andrew Jackson; Lawrence B Marks; Randall K Ten Haken; Ellen D Yorke Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-01 Impact factor: 7.038
Authors: Gonzalo Sapisochin; Aisling Barry; Mark Doherty; Sandra Fischer; Nicolas Goldaracena; Roizar Rosales; Moises Russo; Rob Beecroft; Anand Ghanekar; Mamatha Bhat; James Brierley; Paul D Greig; Jennifer J Knox; Laura A Dawson; David R Grant Journal: J Hepatol Date: 2017-02-28 Impact factor: 25.083
Authors: Jin-Kyu Kang; Mi-Sook Kim; Chul Koo Cho; Kwang Mo Yang; Hyung Jun Yoo; Jin Ho Kim; Sun Hyun Bae; Da Hoon Jung; Kum Bae Kim; Dong Han Lee; Chul Ju Han; Jin Kim; Su Cheol Park; Young Han Kim Journal: Cancer Date: 2012-05-08 Impact factor: 6.860